Excessive glutamate receptor activity, principally of theN-methyl-D-aspartate (NMDA) subtype, contributes to neuronal damage in a large number of neurologic disorders, including dementia. Until ...

Memantine, an uncompetitive NMDA-receptor antagonist, could be of therapeutic value in Alzheimer's disease. 12 A recent study in patients with advanced dementia (Alzheimer's disease and vascular ...

Memantine blocks some NMDA receptors when they're too active. The combination of memantine and a cholinesterase inhibitor leads to modest improvements in cognition and global outcomes in patients ...

August 24, 2010 — The adamantine derivative, memantine, preferentially blocks excessive extrasynaptic activity of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors (NMDAR), while ...

The results show a distinct distribution of NMDA receptors in the cortex of patients with Alzheimer's disease, ... as memantine, one of the most commonly used drugs for the disease, ...

Memantine, an NMDA receptor antagonist, is one of only four drugs approved for AD. “The NMDA receptor is so important for disease, and there has been an enormous effort to design different compounds ...

Memantine is a non-competitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, approved by the U.S. Food and Drug Administration (FDA) for treatment of Alzheimer’s disease and ...

"Most NMDA receptors are found in synapses, where they enhance neuronal connections. However, ... as memantine, one of the most commonly used drugs for the disease, ...

Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl D-aspartate (NMDA) receptor antagonist which binds ...

Memantine belongs to a class of drugs called NMDA receptor antagonists. A class of drugs is a group of medications that work in a similar way. These drugs are often used to treat similar conditions.

Innovative protocol maps NMDA receptors in Alzheimer's-Affected brains. Universidad Miguel Hernandez de Elche. Funder Fondo de Investigaciones Sanitarias, Direcció General de Ciència i ...